subcutaneous Enoxaparin

DRUG3 trials

Sponsors

University of Colorado, Denver, Centro Hospitalar de Lisboa Central, Zagazig University

Conditions

Fetal Growth RetardationGynecologic CancerPre-EclampsiaPrematurityPsoriasisVenous Thromboembolism

Phase 2

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

CompletedNCT02366871

University of Colorado, DenverGynecologic Cancer, Venous Thromboembolism

Start: 2015-04-28End: 2019-06-30Updated: 2020-03-31

Phase 3

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

Enrolling by invitationNCT04762992

Centro Hospitalar de Lisboa CentralFetal Growth Retardation, Pre-Eclampsia, Prematurity

Start: 2022-07-18End: 2026-12-30Target: 12Updated: 2025-08-13

Unknown Phase

Low-Dose Enoxaparin in Psoriasis

Not yet recruitingNCT06416566

Zagazig UniversityPsoriasis

Start: 2024-05-15End: 2024-10-01Target: 30Updated: 2024-05-16

Related Papers

Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm

JAMA Network Open2020-06-26120 citations

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Frontiers in Oncology2019-02-2633 citations